Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 7/20 | 0.60 |
| ▸ | JAK2 | O60674 | 6/20 | 0.60 |
| ▸ | JAK1 | P23458 | 5/20 | 0.60 |
| ▸ | JAK3 | P52333 | 5/20 | 0.60 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16909248 | 1.00 | TYK2 (0.60) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL20459485 | 1.00 | TYK2 (0.60) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL16909282 | 0.90 | TYK2 (0.73) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL16909292 | 0.89 | TYK2 (0.47) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL20459484 | 0.89 | TYK2 (0.47) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL16909247 | 0.86 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL16909275 | 0.85 | TYK2 (0.44) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL18409119 | 0.85 | TYK2 (0.62) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL18398513 | 0.85 | TYK2 (0.62) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL18409549 | 0.85 | TYK2 (0.62) | TYK2JAK2JAK1JAK3MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-05-23 | — | — | US | disclosed |
| US-10179771-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2019-01-15 | — | — | US | disclosed |
| EP-3097083-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-08-08 | — | — | EP | disclosed |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9440929-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440929-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-09-13 | — | — | US | disclosed |
| WO-2015110378-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-07-30 | — | — | WO | disclosed |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | TYK2 41/4885JAK2 5/4885JAK1 1/4885 |
| US-10179771-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | JAK1, JAK3, IL6 | TYK2 31/4885JAK2 4/4885JAK1 1/4885 |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | TYK2 41/4885JAK2 5/4885JAK1 1/4885 |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | TYK2 41/4885JAK2 5/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.